---
title: "北森控股發佈年度業績 股東應占虧損 1.47 億元 同比收窄 95.41%"
description: "智通財經 APP 訊，北森控股發佈截至 2025 年 3 月 31 日止年度的年度業績，源自客户合約的收入 9.45 億元 (人民幣，下同)，同比 10.57%;股東應占虧損 1.47 億元，同比收窄 95.41%;每股基本虧損 0.2 元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/245313470.md"
published_at: "2025-06-19T15:14:03.000Z"
---

# 北森控股發佈年度業績 股東應占虧損 1.47 億元 同比收窄 95.41%

> 智通財經 APP 訊，北森控股發佈截至 2025 年 3 月 31 日止年度的年度業績，源自客户合約的收入 9.45 億元 (人民幣，下同)，同比 10.57%;股東應占虧損 1.47 億元，同比收窄 95.41%;每股基本虧損 0.2 元。

智通財經 APP 訊，北森控股 (09669) 發佈截至 2025 年 3 月 31 日止年度的年度業績，源自客户合約的收入 9.45 億元 (人民幣，下同)，同比 10.57%;股東應占虧損 1.47 億元，同比收窄 95.41%;每股基本虧損 0.2 元。

### Related Stocks

- [09669.HK - 北森控股](https://longbridge.com/zh-HK/quote/09669.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy | Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY | [Link](https://longbridge.com/zh-HK/news/276401882.md) |
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/zh-HK/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-HK/news/276393466.md) |
| Berkshire Hathaway discloses investment in New York Times | Berkshire Hathaway has disclosed a new investment in the New York Times, reentering a sector it left in 2020. The compan | [Link](https://longbridge.com/zh-HK/news/276173033.md) |
| 04:38 ETAcceleronix e IDEMIA Secure Transactions lanzan el programa de acceso anticipado IFPP | Acceleronix and IDEMIA Secure Transactions have launched the IFPP Early Access Program at MWC26 Barcelona, in collaborat | [Link](https://longbridge.com/zh-HK/news/276429430.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。